Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

AJANTA PHARMA LTD.

NSE : AJANTPHARMBSE : 532331ISIN CODE : INE031B01049Industry : Pharmaceuticals & DrugsHouse : Vimal Agrawal

BSE2690.0567.6 (+2.58 %)

PREV CLOSE ( ) 2622.45

OPEN PRICE ( ) 2643.05

BID PRICE (QTY) 2692.10 (1)

OFFER PRICE (QTY) 2700.75 (2)

VOLUME 1838

TODAY'S LOW / HIGH ( )2631.00 2705.00

52 WK LOW / HIGH ( )2022.05 3115

NSE2702.4069.8 (+2.65 %)

PREV CLOSE( ) 2632.60

OPEN PRICE ( ) 2648.00

BID PRICE (QTY) 2700.10 (3)

OFFER PRICE (QTY) 2702.20 (10)

VOLUME 96926

TODAY'S LOW / HIGH( ) 2622.20 2706.50

52 WK LOW / HIGH ( )2327.3 3115.9

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 31-12 1979

Management Info

Mannalal B Agrawal - Chairman Yogesh M Agrawal - Managing Director

Registered Office

Address Ajanta Tower, 54 - A,M V Road, Chakala,Andheri (East),
Mumbai,
Maharashtra-400093

Phone 022-60609000 / 66061000

Email legal.info@ajantapharma.com

Website www.ajantapharma.com

Registrars Details

MUFG Intime India Pvt Ltd.

C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai

Listing : BSE, NSE

NEWS

19Dec Ajanta Pharma informs about disclosures
Ajanta Pharma has informed that the Exchange has received Disclosure und..

06Nov Ajanta Pharma informs about transcrip
Further to its communication dated 3rd November 2025 on earnings call, p..

24Oct Ajanta Pharma informs about update on
With reference to its letter dated 8th October 2025, informing about the..

03Oct Ajanta Pharma informs about updates
Ajanta Pharma has informed that it enclosed Disclosure under Regulation..

16Sep Ajanta Pharma inform about disclosure
Ajanta Pharma has informed that it enclosed disclosure under Regulation..

Financials

Rs. in Millions

	QTR Sep 25	ANNUAL 25
Net Profit	2495.3	9168.9
Gross Profit	3219.7	11800.6
Operating Profit	3646.2	13245.9
Net Sales	12202.4	43220.4

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Fredun Pharma (BSE) 1748.00 (7.19%)	M.Cap ( in Cr)821.57
Alkem Laboratories (BSE) 5637.55 (1.37%)	M.Cap ( in Cr)67433.46
Abbott India (BSE) 28110.00 (0.25%)	M.Cap ( in Cr)59751.97
Astrazeneca Pharma I (BSE) 9130.95 (0.76%)	M.Cap ( in Cr)22794.75
NGL Fine-Chem (BSE) 1335.00 (4.35%)	M.Cap ( in Cr)824.77

Shareholding Pattern

	PROMOTERS	66.25%
	MUTUAL FUNDS/UTI	14.67%
	NON-INSTITUTION	7.32%
	FI/BANKS/INSURANCE	2.64%
	GOVERNMENT	0.01%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
UTI Healthcare Fund...	4.92
Aditya Birla SL Pha...	3.96
NJ ELSS Tax Saver S...	3.47
PGIM India Healthca...	3.28
NJ Flexi Cap Fund-Reg(G)	3.10
Nippon India Pharma...	2.88
Kotak Healthcare Fu...	2.24

Risk Disclosures on Derivatives

Smart Quotes

AJANTA PHARMA LTD.